Last updated: February 16, 2026
What is the current market landscape for Rocuronium Bromide Injection?
Rocuronium Bromide Injection (NDC 00078-0357) is a neuromuscular blocking agent used during anesthesia to facilitate intubation and muscle relaxation for surgical procedures. It primarily competes in a hospital and outpatient surgical setting dominated by a few key players, including Fresenius Kabi and Bedford Laboratories.
The drug's market shares are concentrated among brand and generic versions. The patent originally held by Schering-Plough (now part of Merck) expired in 2009. Since then, multiple generics entered the market, increasing volume but exerting downward pressure on prices.
Market size and volume trends
- In 2022, the US hospital and outpatient prescription volumes for Rocuronium Bromide injections totaled approximately 3.2 million units, reflecting a compound annual growth rate (CAGR) of 2% from 2018-2022 (IQVIA).
- The average annual expenditure on the drug in the US was roughly $400 million, with per-unit prices averaging around $125.
- Usage is projected to increase modestly, driven by growth in surgical procedures requiring neuromuscular blockade and aging demographics.
Competitive landscape
- The market features several manufacturers, with Fresenius Kabi and Bedford Labs (part of Hikma) holding significant shares.
- Several generics are available at lower prices, with recent entries decreasing the price point for the drug.
- Patent exclusivity ended in 2009, enabling a saturated generics market, with price competition intensifying.
Price trends and projections
| Year |
Average Price per Unit |
Market Volume (Units) |
Estimated Market Value |
| 2022 |
$125 |
3.2 million |
$400 million |
| 2023 |
$120 |
3.3 million |
$396 million |
| 2024 |
$115 |
3.4 million |
$391 million |
| 2025 |
$110 |
3.5 million |
$385 million |
Price declines of approximately 4-5% annually reflect increased generic competition and standard market erosion.
Factors influencing future pricing
- Generic market saturation: Further growth in generic manufacturers could lower prices, potentially to around $100 per unit within the next three years.
- Supply chain and production costs: Stabilize or decrease due to advances in manufacturing efficiency, supporting margin preservation.
- Regulatory and reimbursement policies: Increased emphasis on cost containment by hospitals and payers drives downward pressure.
- New formulations or delivery methods: Introduction of alternatives may impact demand and pricing for traditional injection forms.
Market outlook
- The overall market for Rocuronium Bromide is expected to decline marginally in dollar terms over the next five years due to price erosion.
- Volume growth will be modest, contingent on the number of surgical procedures.
- Premium pricing strategies are unlikely, and competition will primarily focus on price reductions.
Key takeaways
- The US market size for NDC 00078-0357 was approximately $400 million in 2022.
- Prices have decreased from an average of $125 per unit in 2022 to an estimated $110 by 2025.
- Increased generic competition and market saturation are primary drivers of price decline.
- Industry projections indicate continued price erosion, with an average decrease of 4-5% annually.
- Volume growth remains steady, but overall value declines slightly due to price pressures.
FAQs
1. What factors could reverse price declines in the Rocuronium market?
Limited generic competition, shortages, or regulatory changes favoring brand-name products could temporarily stabilize or increase prices.
2. Are there any upcoming formulations or alternative drugs that could affect this market?
No significant new formulations or alternatives have been approved recently that would dramatically impact the existing market.
3. How does reimbursement policy impact pricing?
Payers increasingly favor cost-effective options, pressuring hospitals to choose lower-cost generics, accelerating price declines.
4. What is the potential for international markets?
Markets outside the US may have different pricing dynamics, often with lower per-unit prices and varying levels of generic competition.
5. How should manufacturers strategize given market trends?
Focusing on cost reduction, ensuring consistent supply, and exploring value-added services can maintain margins amid pricing pressures.
References
[1] IQVIA, 2022 Market Data.
[2] FDA Drug Approvals and Patent Expiry Data.
[3] MarketWatch, 2023. Trends in Hospital Pharmacy Expenditure.
[4] industry reports from Grand View Research and EvaluatePharma.
